In this edition: Buprenorphine XL, provincial Youth Wellness Hubs, how empathy improves patient outc
READ MOREIn this edition: Contigency Management in RAAM clinic, alcohol withdrawal in EDs, working towards so
READ MOREMETA:PHI March webinar presented by Dr. Tany Hauck and Stephanie Rochon
READ MOREIn this edition: interprofessional collaboration, Hep C mobile care and more
READ MOREIn this edition: Auto micro-induction of buprenorphine XL, relationship-building as crucial as metha
READ MOREIn this edition: Thoughts from a semi-retired addiction doctor; mobile crisis intervention program;
READ MOREHappy new year! META:PHI is very excited to announce the release of several new resources: All of th
READ MOREWe have recently produced a set of documents outlining a new framework for making decisions about ta
READ MORETwo new generic methadone products have been added to the Ontario provincial formulary. As of Septem
READ MOREThese materials are intended for EDs and hospitals who want to set up their own take-home naloxone p
READ MOREThese recommendations for the management of alcohol-related emergency department (ED) presentations were developed by a group of people with professional and/or experiential expertise of alcohol use. Part of Toolkit for Alcohol-Related Presentations to the Emergency Department Version date: 15 December 2023
Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT). Authors: Karan Cheema, Meldon Kahan, Jason Rodgers, Ashley Smoke, Suzanne Turner, Jennifer Wyman, Maria Zhang Reviewers: Lisa Bromley, Katie Dunham, Caryn Green, Janelle Hannon, Christina Henry, Cassandra Huck, Laura Jones, Kate Lazier, Andrew McLeod, Charlotte Munro, Patrick Nowak, Lori Regenstreif, Michael Roach, Elizabeth Shouldice, Anita Srivastava Design: Brent Logan Version date: 01 November 2023
A plain-language summary of the document “Recommendations for the use of slow-release oral morphine as opioid agonist therapy”, intended for patients interested in learning about slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT). Authors: Karan Cheema, Meldon Kahan, Jason Rodgers, Ashley Smoke, Suzanne Turner, Jennifer Wyman, Maria Zhang Reviewers: Lisa Bromley, Katie Dunham, Caryn Green, Janelle Hannon, Christina Henry, Cassandra Huck, Laura Jones, Kate Lazier, Andrew McLeod, Charlotte Munro, Patrick Nowak, Lori Regenstreif, Michael Roach, Elizabeth Shouldice, Anita Srivastava Design: Brent Logan Version date: 01 November 2023
A tool for patients to use with their health care providers to help them decide what opioid agonist therapy (OAT) option would be best for them: sublingual buprenorphine (Suboxone), depot buprenorphine (Sublocade), methadone, or slow-release oral morphine (Kadian). Authors: Karan Cheema, Meldon Kahan, Jason Rodgers, Ashley Smoke, Suzanne Turner, Jennifer Wyman, Maria Zhang Reviewers: Lisa Bromley, Katie Dunham, Caryn Green, Janelle Hannon, Christina Henry, Cassandra Huck, Laura Jones, Kate Lazier, Andrew McLeod, Charlotte Munro, Patrick Nowak, Lori Regenstreif, Michael Roach, Elizabeth Shouldice, Anita Srivastava Design: Brent Logan Version date: 01 November 2023
76 Grenville St.
Toronto, ON M5S 1B2
416-323-6400 x7511
Kate Hardy
Network Director
Ontario Ministry of Health
Program Sponsor